Citigroup’s Juno Therapeutics, Inc. JUNO Stock Holding History

Citigroup’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-46,700	Closed	-$2.13M	–	7813
2017 Q4	$2.13M	Sell	46,700 -11,900	-20%	-$594K	﹤0.01%	2610
2017 Q3	$2.63M	Buy	58,600 +28,400	+94%	+$968K	﹤0.01%	2375
2017 Q2	$903K	Buy	30,200 +9,900	+49%	+$244K	﹤0.01%	3434
2017 Q1	$450K	Sell	20,300 -4,500	-18%	-$96.5K	﹤0.01%	3960
2016 Q4	$467K	Sell	24,800 -3,900	-14%	-$95.4K	﹤0.01%	4441
2016 Q3	$861K	Sell	28,700 -6,300	-18%	-$196K	﹤0.01%	3384
2016 Q2	$1.34M	Sell	35,000 -19,400	-36%	-$805K	﹤0.01%	2669
2016 Q1	$2.07M	Buy	54,400 +15,500	+40%	+$540K	﹤0.01%	2451
2015 Q4	$1.71M	Buy	38,900 +2,900	+8%	+$144K	﹤0.01%	2608
2015 Q3	$1.47M	Buy	36,000 +3,200	+10%	+$140K	﹤0.01%	2730
2015 Q2	$1.75M	Buy	+32,800	New	+$1.74M	﹤0.01%	2657

Other funds holding JUNO

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Citigroup's JUNO Position: Q1 2018 in Review

Citigroup sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 83,438 shares — an estimated $3.81M sold.

Citigroup first reported a position in JUNO in Q1 2015 and held it in 12 quarters. The position peaked at $4.84M in Q4 2016. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

Citigroup reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Citigroup sold 83,438 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $3.81M.
Citigroup first reported a position in Juno Therapeutics, Inc. in Q1 2015 and held it in 12 quarters.
Citigroup's Juno Therapeutics, Inc. position peaked at $4.84M in Q4 2016.
2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Citigroup's 13F filing for Q1 2018, filed 11 May 2018.